Structured evidence table for Omega-3 Visual Fatigue Meta-Analysis, generated from 1 reusable source document in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Omega-3 Visual Fatigue Meta-Analysis | 6 8 9 10 11 12 13 14 15 16 17 Although the etiology of MS is not yet fully understood, accumulating evidence suggests that its onset and progression are driven by an intricate interplay between genetic predisposition and environmental factors [–]. | 4 | Wang Yuxin (2026) | Adjunctive strategies in multiple sclerosis treatment: non-pharmacological approaches and their potential clinical implications |
| Omega-3 Visual Fatigue Meta-Analysis | Based on that, recent advances in disease-modifying therapies (DMTs) of MS, particularly the B-cell depletion therapies like ocrelizumab [], have shown efficacy in mitigating disease activity and managing relapse-associated symptoms by targeting peripheral immunity (via immunoregulatory, anti-migratory, or depleting mechanisms) []. | 4 | Wang Yuxin (2026) | Adjunctive strategies in multiple sclerosis treatment: non-pharmacological approaches and their potential clinical implications |
| Omega-3 Visual Fatigue Meta-Analysis | First, systemic immunosuppression weakens the immune system of MS patients, leading to increased susceptibility to opportunistic infections and malignancies []. | 4 | Wang Yuxin (2026) | Adjunctive strategies in multiple sclerosis treatment: non-pharmacological approaches and their potential clinical implications |
| Omega-3 Visual Fatigue Meta-Analysis | 1 2 3 4 5 Multiple sclerosis (MS) is a chronic inflammatory neurodegenerative disease of the central nervous system (CNS), and one of the most common causes of non-traumatic disability in young adults aged 18 to 40 years, affecting approximately 2.8 million people worldwide []. | 4 | Wang Yuxin (2026) | Adjunctive strategies in multiple sclerosis treatment: non-pharmacological approaches and their potential clinical implications |
Source documents